Latest
Science & Space

Daily Pancreatic Cancer Pill Trial Leaves Tumors Undetectable in Roughly 1 in 12 Patients

Updated Phase 1/2 data presented at ENA 2026 in Barcelona show oral pan-RAS inhibitor daraxonrasib plus chemotherapy shrank tumors in 60.7% of first-line metastatic pancreatic cancer patients, though doctors stress it is not a cure.

Read the story
Science & Space · Read the story
Newstro Science & Space section banner.
Newstro
Share this story

Oral pill trial delivers rare complete responses in advanced pancreatic cancer

Barcelona — November 20, 2026 · 11:46 a.m. CST (17:46 UTC).

A targeted daily pill called daraxonrasib helped wipe out detectable tumors on CT scans in roughly one in 12 patients with advanced pancreatic cancer during a closely watched clinical trial, researchers reported this week—sparking optimism among oncologists alongside firm warnings not to call the treatment a cure.

Updated Phase 1/2 results from the RMC-GI-102 trial, presented at the EORTC-NCI-AACR (ENA) Symposium in Barcelona and reported Friday by BBC News, The Independent, and The Telegraph, tested daraxonrasib alongside standard chemotherapy in 61 previously untreated patients whose pancreatic ductal adenocarcinoma had already spread.

In 8.2% of those patients—about one in 12—tumors became completely undetectable on follow-up scans, according to data released by developer Revolution Medicines via GlobeNewswire. Overall, 60.7% of trial participants saw significant tumor shrinkage, while disease growth stopped in 90.2% of patients.

How the drug targets a mutation long considered undruggable

Pancreatic cancer has long ranked among the most lethal solid tumors in medicine, largely because it is frequently diagnosed after spreading and responds poorly to standard chemotherapy alone. More than 90% of pancreatic tumors carry mutations in the KRAS gene, which acts like a stuck accelerator pedal driving nonstop cell growth.

Daraxonrasib—marketed under the brand name Rasonque and previously known as RMC-6236—is an oral pan-RAS(ON) inhibitor designed to lock onto and block active mutated RAS proteins. In the Barcelona presentation, Memorial Sloan Kettering Cancer Center medical oncologist Dr. Wungki Park paired the once-daily pill with gemcitabine and nab-paclitaxel as a first-line regimen.

Beyond tumor shrinkage, the trial posted a median progression-free survival of 12.8 months and an estimated 12-month overall survival rate of 76.6% over a median follow-up of 18.3 months, according to the study release—well above typical one-year survival rates of roughly 40% to 45% seen historically with standard chemotherapy alone.

Why cancer specialists urge caution despite ‘biggest leap’ praise

While British outlets including LBC and The Telegraph noted that cancer charities and researchers hailed the pill as the “biggest leap forward in decades,” physicians involved in pancreatic cancer care stressed that an undetectable scan does not guarantee permanent eradication of microscopic cancer cells.

In clinical oncology, a “complete response” means imaging scans can no longer see the tumor, not that a patient is definitively cured. Larger, randomized Phase 3 trials with longer follow-up are required to confirm whether first-line combination therapy extends survival across broader patient groups and how long remissions last.

The first-line data build on Revolution Medicines’ separate Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, which helped secure U.S. Food and Drug Administration approval in August 2026 and European Commission approval in mid-November 2026 for second-line patients.

Where the ENA 2026 data were presented

The updated RMC-GI-102 clinical trial findings were presented as a late-breaking abstract at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

★ Barcelona, Spain, host city of the ENA 2026 Symposium. Map data: OpenStreetMap contributors, ODbL. Open map.

Timeline of daraxonrasib milestones

  1. — U.S. FDA approves daraxonrasib (Rasonque) for previously treated metastatic pancreatic cancer following the Phase 3 RASolute 302 trial.
  2. — European Commission grants approval for daraxonrasib in second-line metastatic pancreatic cancer.
  3. — Dr. Wungki Park presents updated first-line Phase 1/2 RMC-GI-102 data (61 patients; 8.2% complete response rate; 76.6% 12-month survival) at the ENA 2026 Symposium in Barcelona.

Sources and visual credits

Sources: BBC News, The Independent, The Telegraph, LBC, and Revolution Medicines via GlobeNewswire.

Visuals: Newstro.